TargetScan, a new device that provides a stationary probe to eliminate prostate movement during certain prostate cancer treatments, will now be distributed to physicians nationwide through an exclusive agreement between Envisioneering Medical Technologies, the product?s developer, and BrachySciences.
TargetScan, a new device that provides a stationary probe to eliminate prostate movement during certain prostate cancer treatments, will now be distributed to physicians nationwide through an exclusive agreement between Envisioneering Medical Technologies, the product’s developer, and BrachySciences.
“This agreement places new technology that can improve prostate cancer treatment outcomes directly in the hands of doctors to benefit their patients,” said Robert G. Mills, Envisioneering president.
According to Mills, TargetScan addresses unmet treatment planning and brachytherapy seed placement needs of radiation oncologists. In addition to eliminating prostate movement during treatments, the system offers improved 3-D imaging, with views of both sagittal and transverse planes.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.